Fintel reports that on October 4, 2023, HC Wainwright & Co. reiterated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with a Buy recommendation.
Analyst Price Forecast Suggests 374.56% Upside
As of August 31, 2023, the average one-year price target for Aclaris Therapeutics is 29.71. The forecasts range from a low of 16.16 to a high of $45.15. The average price target represents an increase of 374.56% from its latest reported closing price of 6.26.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Aclaris Therapeutics is 7MM, a decrease of 77.93%. The projected annual non-GAAP EPS is -1.68.
What is the Fund Sentiment?
There are 310 funds or institutions reporting positions in Aclaris Therapeutics. This is a decrease of 17 owner(s) or 5.20% in the last quarter. Average portfolio weight of all funds dedicated to ACRS is 0.19%, an increase of 11.22%. Total shares owned by institutions decreased in the last three months by 0.08% to 75,216K shares. 
The put/call ratio of ACRS is 0.68, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 7,638K shares representing 10.79% ownership of the company. In it's prior filing, the firm reported owning 7,373K shares, representing an increase of 3.47%. The firm increased its portfolio allocation in ACRS by 26.72% over the last quarter.
Ra Capital Management holds 4,398K shares representing 6.21% ownership of the company. No change in the last quarter.
Rock Springs Capital Management holds 3,962K shares representing 5.60% ownership of the company. No change in the last quarter.
Bain Capital Life Sciences Investors holds 3,400K shares representing 4.80% ownership of the company. No change in the last quarter.
Bvf holds 3,361K shares representing 4.75% ownership of the company. No change in the last quarter.
Aclaris Therapeutics Background Information
(This description is provided by the company.)
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
